HOW WE HELP
NET Cancer is the FASTEST growing class of CANCER worldwide
HELP US HELP OTHERSNeuroendocrine Tumours (NETs) Overview
- Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
- NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
- NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
- NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
- The cause of NETs is currently unknown.
CONTACT US
SUPPORT LINES:
416-628-3189
Toll Free: 1-844-628-6788
EMAIL:
CNETS NEWS
European Journal of Cancer Article
Article: Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era February 2021 - European Journal of Cancer, Review Article on "Practical recommendations for [...]
INCA NETInfo
INCA GLOBAL NET PATIENT INFO PACK NEW FOR 2020! - NETInfo INCA launches a range of factsheets on NETs that are free to download. These factsheets provide comprehensive information on NETs and [...]
LUTATHERA® Funded in Ontario
Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed on [...]
LUTATHERA® Funded in Quebec
As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients with advanced disease that is [...]
LUTATHERA® Funded in Nova Scotia
As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed [...]
#HoofingIt launches at Peggy’s Cove July 1
HOOFING IT - The summer-long fundraiser launched at Peggy's Cove on July 1st. Sharon Needham, lung neuroendocrine cancer survivor and advocate; family, friends, supporters kicked-off HOOFING IT with a 5km walk along Peggy's Cove [...]
CNETS PRIORITIES
SUPPORT
- In-person peer-led support groups meetings
- Dedicated patient email and phone support
- Online private support groups for patients & caregivers
EDUCATION
- Patient and caregiver education sessions across Canada
- Robust online patient educational resources
- Printed educational resources including the NET Reference Guide
- Annual NET Medical and Scientific Meeting
AWARENESS
- Raise awareness of NET cancer to the general public & the medical community
- Participate in World NET Cancer Day Activities
